What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis

Emma Simpson,¹* Emma Hock,¹ Matt Stevenson,¹ Ruth Wong,¹ Naila Dracup,¹ Allan Wailoo,¹ Philip Conaghan,^{2,3} Cristina Estrach,⁴ Christopher Edwards⁵ and Richard Wakefield^{2,3}

Declared competing interests of authors: Richard Wakefield has provided consulting advice and spoken for General Electric with regard to ultrasound technologies and has also received speaker fees from AbbVie Inc. for ultrasound-related projects. Cristina Estrach has been a member of advisory boards for and/or received speaker fees from AbbVie Inc., Chugai Pharma (UK) Ltd and General Electric Co. Her institution has received educational grants from Pfizer Inc.

Published April 2018 DOI: 10.3310/hta22200

¹School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

³National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK

⁴Aintree University Hospitals NHS Foundation Trust, Liverpool, UK

⁵National Institute for Health Research (NIHR) Wellcome Trust Clinical Research Facility, University of Southampton, Southampton, UK

^{*}Corresponding author e.l.simpson@sheffield.ac.uk

Plain English summary

Ultrasound joint examination for monitoring synovitis in rheumatoid arthritis

Health Technology Assessment 2018; Vol. 22: No. 20

DOI: 10.3310/hta22200

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Plain English summary

The aims of this study were to investigate the value of ultrasound (US) in addition to clinical examination (CE) for monitoring synovitis (swelling of joint synovial lining) in rheumatoid arthritis (RA) and whether or not US could be used to make treatment decisions. A systematic literature review identified 58 studies providing relevant evidence. Studies indicated that US-detected synovitis was associated with later development of structural progression assessed by radiography, a sign that RA is causing permanent joint damage. Studies suggested that US was better than CE at predicting response to treatment and tapering (dose reduction) or discontinuation of a particular treatment. US was used to make treatment decisions and could increase clinician and patient confidence in those decisions. However, studies varied in the types of US and CE that were used and how outcomes were measured, making it difficult to draw firm conclusions about the overall usefulness of adding US to CE.

No studies on the cost-effectiveness of US for monitoring synovitis were identified, but studies assessing the impact of reducing treatment doses were identified. These reported that some patients who had achieved good control of their disease could have their treatment reduced without harmful effects. It may also be possible to withdraw treatment for some patients although this is rare in established RA. Reduced dosages can save large sums of money in terms of drug costs. It was estimated that a 2.5% reduction in dose of biological treatment would more than pay for the use of US every 3 months. The reduction in dose needed to cover the costs of US rose when less expensive treatments were used but did not become larger than 6%, assuming that multiple cheaper treatments were used. It appears likely that using US to monitor synovitis could potentially represent value for money. However, more evidence is needed to reduce the uncertainty in the current findings.

HTA/HTA TAR

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.236

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 14/16/01. The contractual start date was in January 2015. The draft report began editorial review in April 2016 and was accepted for publication in August 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Health Technology Assessment Editor-in-Chief

Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk